AbobotulinumtoxinA (Dysport)
Defines medical necessity, initial and continued approval criteria, dosing limits, prescriber requirements, and documentation expectations for Dysport across multiple neurologic and related indications for Centene-affiliated health plans.
Revised continued therapy max dose for chronic migraine from 155 units to 250 units.
Allowed continued approval of sialorrhea from 12 weeks to 16 weeks to match initial approval duration.
Revised max dose for blepharospasm from 60 units to 120 units and clarified 120 units per eye per treatment session.
For overactive bladder, updated criteria to require use of two anticholinergic agents or one oral beta-3 agonist (previously both were required) and revised Medicaid/HIM approval durations to 12 months.
Clarified continued approval duration for esophageal achalasia for second dose versus beyond.
Added step therapy bypass for IL HIM per IL HB 5395.
Commercial approval duration revised to '6 months or to member's renewal date, whichever is longer' for injectables.
2Q 2026 annual review: no significant changes; references reviewed and updated.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.